drugset / Trial / NCT04261075
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability and to determine the dose of IPH5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.
Timeline
- Start
- 2020-03-03
- Primary completion
- 2022-06-16
- Completion
- 2022-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | IPH5201 | Unknown | — | — |
| Subject | Oleclumab | Monoclonal antibody | — | — |